title: Hepatocellular carcinoma: locoregional and targeted therapies.
abstract: HCC is a leading cause of morbidity and mortality worldwide. Advances in cancer screening and surveillance have allowed for earlier detection of tumors, affording greater treatment potential. The advent of locoregional therapies has generated greater treatment options for patients with HCC. Either alone or in combination as an adjuvant or neoadjuvant therapy, these novel approaches continue to hold promise for improving morbidity and/or mortality of patients with HCC. The emergence of systemic molecular targeted therapies increases the role of translational science. Whereas surgical resection and transplantation conventionally form the cornerstone of curative approaches, the advancement of locoregional therapies holds great promise in adding to the curative armamentarium.
authors: Stanford University School of Medicine, Division of Gastroenterology and Hepatology, Alway Building, Room M211, 300 Pasteur Drive, MC: 5187, Stanford, CA 94305-5187, USA.
authors: Robert
authors: R
authors: Wong
authors: Catherine
authors: C
authors: Frenette
authors: Robert
authors: R
authors: Gish
mesh_terms: D055011:Ablation Techniques; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D004621:Embolization, Therapeutic; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D058990:Molecular Targeted Therapy